https://www.prognyx.com/blog/replimune-s-own-filing-shows-the-rp1-melanoma-pivotal-was-a-single-arm-cohort-thPrognyxen2026-07-29Replimune's own filing shows the RP1 melanoma pivotal was a single-arm cohort — the randomized answer is dated 2030 https://www.prognyx.com/blog/astrazeneca-s-cldn18-2-adc-won-a-late-stage-trial-with-a-caveat-and-the-caveat-iPrognyxen2026-07-28Sonesitatug vedotin won overall survival in CLARITY-Gastric01 and missed its PFS co-primary — and moved the CLDN18.2 bar to 25%